Genetic factors that confer sensitivity to HAART in HIV-infected subjects: Implication of a benefit of an earlier initiation of HAART

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1347-1351

  Nakajima, Toshiaki ^a   Kimura, Akinori ^a  

^a Tokyo Medical and Dental University ^*  (Japan)

Author keywords

CCL3L1; CCR5; HAART; HIV 1; HLA

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HLA ANTIGEN; HLA B ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; EARLY INTERVENTION; GENE DUPLICATION; GENE IDENTIFICATION; GENE INTERACTION; GENE NUMBER; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACOGENETICS; POPULATION GENETICS; PREDICTION; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; T CELL DEPLETION; VIRUS INHIBITION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENOTYPE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; RISK FACTORS; TIME FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 55449134748     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1347     Document Type: Article

References (24)

1. Ahuja SK, Kulkarni H, Catano G, et al.: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat. Med. 14(4), 413-420 (2008).
2. The Joint United Nations Programme on HIV/AIDS (UNAIDS) AIDS Epidemic Update: December 2007 (UNAIDS, Geneva, Switzerland, 2007).
3. Brumme ZL, Brumme CJ, Chui C et al.: Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J. Infect. Dis. 195(11), 1694-1704 (2007).
4. Rauch A, Nolan D, Furrer H et al.: Swiss HIV Cohort Study: HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy. Clin. Infect. Dis. 46(12), 1921-1925 (2008).
5. Bratt G, Karlsson A, Leandersson AC et al.: Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 12(16), 2193-2202 (1998).
6. Valdez H, Purvis SF, Lederman MM et al.: Association of the CCR5Δ32 mutation with improved response to antiretroviral therapy. JAMA 282(8), 734 (1999).
7. O'Brien TR, McDermott DH, Ioannidis JP et al.: Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy AIDS 14(7), 821-826 (2000).
8. Kasten S, Goldwich A, Schmitt M et al.: Positive influence of the Δ32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur. J. Med. Res. 5(8), 323-328 (2000).
9. Laurichesse JJ, Persoz A, Theodorou I, Rouzioux C, Delfraissy JF, Meyer L: Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 AD32 deletion. HIV Med. 8(4), 213-219 (2007).
10. Arenzana-Seisdedos F, Parmentier M: Genetics of resistance to HIV infection: Role of co-receptors and co-receptor ligands. Semin. Immunol. 18, 387-403 (2006).
11. O'Brien SJ, Nelson GW: Human genes that limit AIDS. Nature Genet. 36, 565-574 (2004).
12. Samson M, Libert F, Doranz BJ et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382, 722-725 (1996).
13. Liu R, Paxton WA, Choe S et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
14. Gonzalez E, Kulkarni H, Bolivar H et al.: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307, 1434-1440 (2005).
15. Nakajima T, Ohtani H, Naruse T et al.: Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia. Immunogenetics 59, 793-798 (2007).
16. Kaslow RA, Dorak T, Tang J: Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect. Dis. 191, S68-S77 (2005).
17. Gao X, Bashirova A, Iversen AKN et al.: AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis. Nature Med. 11, 1290-1292 (2005).
18. Balla-Jhagjhoorsingh SS, Koopman G, Mooij P et al.: Conserved CTL epitopes shared between HIV-infected human long-term survivors and chimpanzees. J. Immunol. 162(4), 2308-2314 (1999).
19. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
20. Mallal S, Phillips E, Carosi G et al.: HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
21. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
22. Fellay J, Shianna KV, Ge D et al.: A whole-genome association study of major determinants for host control of HIV-1. Science 317, 944-947 (2007).
23. Dolan MJ, Kulkarni H, Camargo JF et al.: CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat. Immunol. 8, 1324-1336 (2007).
24. Shalekoff S, Meddows-Taylor S, Schramm DB et al.: Host CCL3L1 gene copy number in relation to HIV-1-specific CD4+ and CD8+ T-cell responses and viral load in South African women. J. Acquir. Immune Defic. Syndr. 48(3), 245-254 (2008).